Regulus Therapeutics, Inc.
(NASDAQ : RGLS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SAVACassava Sciences, Inc. 12.23%87.040.0%$239.29m
HZNPHorizon Therapeutics Plc 0.64%95.035.5%$179.97m
VRXValeant Pharmaceuticals International, Inc. 1.75%29.5914.1%$174.11m
JAZZJazz Pharmaceuticals Plc 1.11%178.952.2%$124.11m
ICLRICON plc 2.05%215.044.2%$120.64m
CTLTCatalent, Inc. 0.80%109.962.1%$97.18m
SAGESAGE Therapeutics, Inc. 1.56%57.267.6%$75.58m
ARGXargenx SE 2.47%319.860.0%$65.22m
UTHRUnited Therapeutics Corp. 0.11%174.8314.0%$65.04m
BHCBausch Health Cos., Inc. 1.75%29.590.0%$57.60m
PRGOPerrigo Co. Plc 0.52%46.276.9%$56.22m
PCRXPacira Biosciences, Inc. 1.06%61.039.9%$29.79m
IRWDIronwood Pharmaceuticals, Inc. 1.82%12.639.6%$24.79m
RVMDRevolution Medicines, Inc. 1.89%33.470.0%$24.73m
AXSMAxsome Therapeutics, Inc. 0.72%70.181.9%$24.14m

Company Profile

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.